Results 41 to 50 of about 1,098,931 (194)

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

Efficacy and Mechanism Evaluation
Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Jonathan A Cook, Piers Patten, Nicholas Peckham, Paul Moss, Abhishek Abhishek, Vicki S Barber, Anne Francis, Lelia Duley, Robbert Hoogeboom, Brian J Willett, Gratian Vandici, Gareth Plested, Lucy Eldridge, Patrick Julier, Thomas Roberts, Marie Hodges, Helen M Parry   +16 more
doaj   +1 more source

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch, Markus Matilainen, Giulia N. Baldrighi, Marjo Nylund, Maija Saraste, Laura Airas   +5 more
wiley   +1 more source

B Cells are Activated via a Nanoporous Interface that Stabilizes Microvilli and Engages Mechanosensitive Ion Channels

Advanced Science, EarlyView.
B cells can be activated independently of antigen recognition via mechanical stimulation through nanoporous substrates. Exposure to such substrates induced B cell microvilli extension into the pores, intracellular Ca2+ signaling, phosphorylation of signaling proteins, and CD69 expression.
Nozie D. Aghaizu, Willi Weber, Nadine Strempel, Asya Polat, Enrico Klotzsch   +4 more
wiley   +1 more source

Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. [PDF]

, 2021
Novel targeted cancer therapies have revolutionized oncology therapies, but these treatments can have cardiovascular complications, which include heterogeneous cardiac, metabolic, and vascular sequelae.
Barac, Ana, Beckman, Joshua, Moslehi, Javid, Jackson, Klarissa, Xiao, Ling, Fleming, Matthew   +5 more
core   +1 more source

Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report

AIDS Research and Therapy, 2023
Background Despite increasing effort for treating primary central nervous system lymphoma (PCNSL), the prognosis of human immunodeficiency virus (HIV) -related PCNSL was still unsatisfactory.
Ying Zhou, Xiaoxue Wang, Xuyong Lin, Jun Wang, Xiaojing Yan, Ying Wen   +5 more
doaj   +1 more source

A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications

Molecules, 2023
Bruton tyrosine kinase (BTK) is an essential enzyme in the signaling pathway of the B-cell receptor (BCR) and is vital for the growth and activation of B-cells.
Qi Zhang, Changming Wen, Lijie Zhao, Yatao Wang   +3 more
doaj   +1 more source

Single‐Cell Transcriptomic Profiling Identifies B Cell‐Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia

Advanced Science, EarlyView.
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo, Yanxia Zhan, Lili Ji, Pengcheng Xu, Pu Chen, Hao Pang, Yunan Ling, Fanli Hua, Xibing Zhuang, Hao Chen, Yunfeng Cheng   +10 more
wiley   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber, Mario R. Angeli, Hashem Mohammadian, Hannah Labinsky, Maria Gabriella Raimondo, Richard Demmler, Yuko Ariza, Thomas Wohlfahrt, Markus Luber, Yi‐Nan Li, Jörg H.W. Distler, Tobias Bäuerle, Georg Schett, Simon Rauber, Andreas Ramming, Alina M. Ramming   +15 more
wiley   +1 more source

Treatment‐driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B‐cell therapy in Sjögren's disease

Arthritis &Rheumatology, Accepted Article.
Objective To characterise whole‐blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or BlyS/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to non‐response. Methods Whole‐blood RNA sequencing was performed at baseline and week‐24 in participants (n=43) from a
Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin‐Gutierrez, John Casement, Kyle Thompson, Wan‐Fai Ng, André van Maurik, Elizabeth C Jury, Coziana Ciurtin   +9 more
wiley   +1 more source

Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE)

Journal of International Medical Research
Objective Bruton tyrosine kinase inhibitors and B-cell lymphoma 2 inhibitors are currently the new standard active agents in chronic lymphocytic leukaemia. This observational study describes the real-world use of frontline treatment in Bulgarian patients
Vasko Graklanov, Atanas Radinoff, Ilina Micheva, Merlin Erol Efraim, Martin Donchev, Tanya Yankova, Vanya Slavcheva-Popova, Silvia Naneva, Evgueniy Hadjiev, Liana Gercheva-Kyuchukova, Martina Petrova-Latkova, Ivan Nikolov, Alexander Nenov, Alen Ostojić, Stanislava Krasteva, Zhanet Grudeva-Popova   +15 more
doaj   +1 more source